APA (7th ed.) Citation

Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, . . . Juday T. (2012). Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective. Dove Medical Press.

Chicago Style (17th ed.) Citation

Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, and Juday T. Cost-effectiveness of Entecavir Versus Adefovir for the Treatment of Chronic Hepatitis B in Patients with Decompensated Cirrhosis from a Third-party US Payer Perspective. Dove Medical Press, 2012.

MLA (9th ed.) Citation

Tsai N, et al. Cost-effectiveness of Entecavir Versus Adefovir for the Treatment of Chronic Hepatitis B in Patients with Decompensated Cirrhosis from a Third-party US Payer Perspective. Dove Medical Press, 2012.